Ultrasound contrast agents (UCA), in conjunction with contrast specific imaging techniques, are increasingly accepted in clinical use for diagnostic imaging and post-interventional workup in several organs. Presently, there is no guidance document providing a description of essential technical requirements, proposed investigator qualifications, suggested investigational procedures and steps, guidance on image interpretation, recommended and established clinical indications and safety considerations.
These guidelines are based on comprehensive literature surveys including results from prospective clinical trials. On issues where no significant study data were available, evidence was obtained from expert committee reports or was based on the actual consensus of experts in the field of US and contrast enhanced Ultrasound (CEUS) during the consensus conference.
These guidelines are intended to create standard protocols for the use and administration of UCA and improve the management of patients. The first version, dated January 2004, will be focused on the evaluation of known or suspected focal liver lesions (FLL).
These guidelines are intended to give general advice for the use of UCA. Individual cases must be managed on the basis of all clinical data available for that specific case. The guidelines will be subject to change to reflect future advances in scientific knowledge and the rapidly evolving field of US technology. 
Introduction
The development of ultrasound contrast agents (UCA), which perform as blood pool tracers, have overcome the limitations of conventional B-Mode and colour or power Doppler US and enable the display of parenchymal microvasculature. Dependent on contrast agent and US-mode, the dynamic lesion enhancement pattern is visualized during intermittent or continuous insonation. Enhancement patterns are described during subsequent vascular phases (e. g. arterial, portal-venous and late phase for liver lesions), similar to contrast enhanced computer tomography (CECT) and/or contrast enhanced magnetic resonance imaging (CEMRI). Contrast enhanced ultrasound (CEUS) and CECT or CEMRI are not fully superimposable, as UCA remain in the intravascular space, whereas the majority of currently approved contrast agents for CT and MRI are rapidly cleared from the blood pool into the extracellular space.
An inherent advantage of CEUS is the possibility to assess the contrast enhancement patterns in real time, without the necessity to predefine scan-timepoints or to perform bolus-tracking and furthermore the possibility to perform repeated examinations due to the excellent patient toleration of UCA. The UCA which are currently used in diagnostic US are characterized by a microbubble structure consisting of gas bubbles stabilized by a shell. UCA act as blood pool agents. They strongly increase the US backscatter and therefore are useful in the enhancement of blood echogenicity for the assessment of blood flow in the vasculature. Levovist contains air whereas SonoVue (sulfur hexafluoride) and Optison (perflutren) contain low solubility gases improving microbubble stability.
The assessment of microbubbles usually requires contrast specific imaging modes.
Contrast specific US modes are generally based on the cancellation and/or separation of linear US signals from tissue and utilization of the nonlinear response from microbubbles [7 -10] .
Non-linear response from microbubbles is based on two different mechanisms: -non-linear response from microbubble oscillations at low acoustic pressure, chosen to minimize disruption of the microbubbles. -high energy broadband non-linear response arising from microbubble disruption.
Non-linear harmonic US signals may arise also in tissues themselves due to a distortion of the sound wave during its propagation through the tissue. The extent of the harmonic response coming from the tissue is dependent on the MI settings (= mechanical index, which is correlated to the acoustic pressure).
US imaging with air filled microbubble (e. g. Levovist ) leads to microbubble disruption as the resistance to acoustic pressure for these UCA is low. Therefore intermittent imaging with low frame rates to allow refill of the microbubbles into the microvasculature is necessary. Alternatively it is possible to use fast sweep techniques with offline review of the digital stored cine loops.
Low solubility gas UCA (e. g. SonoVue , Optison ) are characterized by the combination of an improved stability with favorable resonance behavior at low acoustic pressure. This allows minimally disruptive contrast specific imaging at low MI and enables effective investigations over several minutes with the visualization of the dynamic enhancement pattern in real time.
Low MI techniques furthermore lead to effective tissue signal suppression, as the non-linear response from the tissue is minimal when low acoustic presssures are used [9 -11] . See systems specification in Appendix 2.
Investigator Training
The EFSUMB minimal training requirements for the practice of medical ultrasound in Europe define three levels of minimal training requirements. It is likely that most UCA examinations would be performed by level 2 or 3 investigators.
It is recommended that investigators wishing to undertake UCA examinations should gain experience by observing contrast studies being performed in a department with expertise in this area. They should also ensure that their equipment is optimised for contrast examination by discussion with their equipment manufacturers. It is also important that in their own department there are adequate numbers of examinations being performed and different types of pathological processes being observed to acquire and maintain their skills.
Practitioners need to be competent in the administration of contrast agents, familiar with any contra-indications and be able to deal with any possible adverse effect, within the medical and legal framework of their country.
Safety Considerations
In general, UCA are extremely safe with a low incidence of side effects. They are not nephrotoxic or cardiotoxic and the incidence of hypersensitivity or allergic events appears much lower than current X-ray or MR contrast agents. It is not necessary to perform laboratory tests of renal function before administering them. UCA are not licensed in pregnancy and breastfeeding is a contra-indication in some countries.
There is a theoretical possibility that the interaction of diagnostic ultrasound and UCA could produce bioeffects. Data from small animal models suggest that microvascular rupture could occur when gas bodies are insonated. This might be a potential safety issue in special situations where such vascular damage would be clinically important such as ocular US and brain without an intact skull. In addition, premature ventricular contractions have been described when high MI end systolic triggering is used in echocardiography.
The MI provides a useful, albeit rough, on-screen indicator of the potential for non-thermal effects. The potential for non-thermal bioeffects exists in all modes, including conventional 2D imaging and 3D methods.
Users should balance the potential clinical benefit from the use of UCA against the theoretical possibility of associated adverse bioeffects in humans.
Some general recommendations would be: 1.5.1 Caution should be considered for the use of UCA in tissues where damage to microvasculature could have serious clinical implications, such as in the brain without an intact skull, the eye, and the neonate. 1.5.2 Investigators should be aware of the possibility of inducing premature ventricular contractions in contrast enhanced echocardiography, when using high MI and end-systolic triggering, and take appropriate precautions. 1.5.3 As in all diagnostic ultrasound procedures, the operator should be mindful of the desirability of keeping the displayed thermal index (TI) low by prudent setting of the controls, and of avoiding unduly long exposure times. 1.5. 4 The use of contrast agents should be avoided 24 hrs prior to extra-corporeal shock wave therapy.
Focal liver lesions (FLL)
In most imaging centers US is the initial examination requested for patients with known or suspected focal liver disease in the sense of either defining the FLL (by their US characteristics, number, size, position) or for ruling out the presence of FLL (as far as possible). Additionally, US imaging frequently reveals hepatic lesions as an incidental finding in patients undergoing an ultrasound examination for screening purposes or for the investigation of a nonhepatic disease.
Once a lesion has been detected, the foremost question is always the differentiation between a benign and malignant lesion. However, since detection and characterization of FLL using unenhanced US is limited to the visualization of grey-scale morphology and macrovascular flow, sensitivity and specificity values of unenhanced ultrasound appear generally inferior to those of dynamic helical (multidetector) CT and MRI, which can exploit contrast enhancement effects for better delineation and characterization of FLL.
Based on characteristic enhancement patterns throughout the vascular phases, CEUS of the liver permits clear improvements in the characterization and detection of FLL when compared to unenhanced US, with close diagnostic agreement with other well established radiological imaging methods such as CECT or CEMRI [12, 13] .
The following recommendations on the application of ultrasound contrast agents for detection and characterization of focal liver lesions and their use in the monitoring of treatment effects following local ablative treatment represent a consensus document issued by the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) with the contribution of experienced experts (see the list above). . This late phase differs from the equilibrium phase of extracellular CT and MRI agents. The origin of this late phase is the subject of ongoing scientific discussion; suggested mechanisms include sinusoid pooling and RES/Kupffer cells uptake [14] .
The arterial phase provides information on the degree and pattern of vascularity. The portal and late phase provide information about the wash out of UCA from the lesion compared to normal liver tissue. In the case of haemangiomas a progressive filling can be observed during these phases. Portal and late phase enhancement can provide important information regarding the character of the lesion: most malignant lesions are hypo-enhancing while the majority of solid benign lesions are iso-or hyper-enhancing [15 -26] .
Investigational Procedure

Low Mechanical Index (MI) Techniques
Low MI contrast specific techniques allow dynamic imaging with subsequent evaluation of the three different vascular phases using a low solubility gas UCA. The typical enhancement patterns are summarized in Table 2a for the following lesions: haemangioma, FNH, focal fatty sparing, focal fatty change, regenerative nodule, cyst, adenoma, abscess).
Malignant Lesions
Malignant lesions are characterized by wash out of microbubbles during the portal and late phase. This is particularly true for liver metastases, while HCC can show some late phase enhancement, or may be isoenhancing.
The arterial phase is important for demonstrating hypervascularity of HCC and hypervascular metastases.
The enhancement patterns for the characterization of malignant lesions (HCC, hypovascular mets, hypervascular mets, cholangio carcinoma) are summarized in Table 2b .
Recommended Use and Indications
Characterization of lesions such as haemangioma, focal nodular hyperplasia, metastasis and HCCs can be obtained at a high level of probability by CEUS in association with clinical and laboratory data, baseline and Doppler US, if typical enhancement patterns are present. Focal liver lesions with atypical enhancement patterns or technically suboptimal studies require further investigation.
Low solubility gas UCA are superior for the use of FLL characterization due to the possibility of dynamic imaging in real time using low MI contrast specific techniques.
Recommended Indications
CEUS is indicated in all patients with uncertain liver lesions, particularly including the following clinical situations: 3 Detection of Focal Liver Lesion
Background
Conventional US is the most frequently used imaging procedure for the primary diagnosis of abdominal organs and the liver, but is less accurate in detection and staging of liver lesions than contrast-enhanced spiral CT and MRI. The main reasons for this are problems in the detection of small sized and/or isoechoic lesions, especially for deep lesions or in difficult anatomical areas (e. g. in the subdiaphragmatic areas).
Clinical studies evaluating CEUS have shown the accuracy to detect liver metastases is improved and may be raised to be comparable to spiral CT. Some studies have suggested CEUS can detect lesions not visible on CT [13, 27 -29] . Most published data, however, relates to intermittent imaging with the late liverspecific phase of Levovist . Published data using the much simpler method of low MI real time scanning using SonoVue is still scanty [30] . However current data from single center and multicentre clinical trials are highly encouraging.
Investigational Procedures 3.2.1 Low Mechanical Index (MI) Techniques
Recommended investigational procedure: 3.2.1.1 Baseline investigation in B-Mode, potentially including Doppler techniques 3.2.1.2 Change to low MI contrast specific imaging mode 3.2.1.3 Using low MI contrast specific imaging modes which lack simultaneous tissue displays it is crucial to provide sufficient tissue cancellation with maintenance of adequate depth penetration. Adequate cancellation of tissue signals is characterized by disappearance of the B-Mode parenchymal liver structures. Major vascular structures and some anatomical landmarks like the diaphragm remain barely visible. 3.2.1.4 UCA is administered as quick bolus followed by a 5 -10 ml saline flush. A stop clock should be started at time of UCA injection 3.2.1.5 A single bolus is usually adequate, and the examination is usually complete within 5 minutes. 3.2.1.6 The complete examination of the liver using various sweeps is possible within a timeframe of approximately 4 -6 min (using all vascular phases). 3.2.1.7 Image Documentation: Essential clips for each vascular phase should be stored digitally on the system hard drive, as DICOM clips and/or MOD according to the technical capacities of the respective systems. 3.2.1.8 Scan in sweeps to cover the whole liver. 3.2.1.9 For hypovascular metastasis detection, the benefit of scanning before 90 s is debatable and some experts would avoid scanning before this time. A common pitfall is that small cysts are sometimes detected on late phase scanning. These can usually be distinguished from metastases as they characteristically show increased through transmission.
High Mechanical Index (MI) Techniques
HCC
Detection of HCCs, especially in the cirrhotic liver, is problematic. They may be detected as areas of increased enhancement in the arterial phase, but the short duration of the arterial phase can make full surveillance of the whole liver problematic. The late phase appearances are variable as previously described but in a proportion of patients HCCs are well shown as relative defects at this time.
Abscess
Abscesses often show enhancement on the arterial phase, usually peripheral, but then washout to appear as relative defects on late phase scanning.
Trauma
Traumatic liver lacerations and haematoma are well shown in all phases as non-enhancing defects. The same method is of value in other solid organs such as the spleen and kidney.
Recommended Use and Indications
Based on published literature [12, 13, 20, 27, 28, 31] , there is evidence that CEUS improves detection of metastases. Some studies have suggested that the accuracy in the detection of intrahepatic metastatic disease is comparable to CECT [13] 
Monitoring of Local Ablative Treatment
Background
Percutaneous ablation therapies play a key role in the management of patients with liver malignancies, both HCC and metastases [32 -36] .
Diagnostic imaging in patients undergoing local ablative treatment includes US, CECT and/or CEMRI during pretreatment diagnostic work-up and at distinct time points within the follow-up of the patient (usually within the first week post treatment and after 1, 3, 6 etc. months).
Unenhanced US, even when combined with color/power Doppler, does not provide any reliable information about the outcome of ablation treatments. In fact, the assessment of vascularization and tissue perfusion is crucial to differentiate, necrosis from residual viable tumor. Biphasic helical CT or dynamic gadolinium-enhanced MRI can predict the extent of the coagulation area to within 2 -3 mm.
When US is used as the imaging modality for guiding ablations, the addition of UCA can provide important information in each of the following procedural steps [37, 38] 
Image Interpretation -Definition of Complete Treatment Response
The most important imaging finding that suggests complete ablation is the disappearance of any previously visualized intralesional enhancement on contrast-enhanced images. Residual viable tumour tissue is suspected when a portion of the original lesion maintains hypervascularity in the arterial phase or clearly enhances in the portal phase.
In hypoenhancing lesions (e. g. most liver metastases), completeness of treatment can be assessed by the comparison of pretreatment lesion size and location with the size and location of the post-treatment coagulation necrotic area. This also determines whether if a sufficient perilesional "safety" margin has been achieved.
In the early (e. g., within the first 30 days) post-ablative evaluation using CEUS, a thin and uniform enhancing rim of hypervascularity can be visible along the periphery of the necrotic area, similar to corresponding findings observed on CECT. Misinterpretation of this perilesional hyperemic halo as residual viable tumour can be avoided by comparing post-ablation images with pre-ablation scans. 
